ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "DexCom, Inc." (DXCM) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"DexCom, Inc." (DXCM)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Health Care Equipment & Supplies
Competitors: BABY, ZLTQ, BVX, EW

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"DexCom, Inc."© quotemedia

Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company offers FDA approved SEVEN, which includes a disposable sensor that can be inserted by a patient and used continuously for up to seven days; a transmitter; and a small handheld receiver. Its SEVEN system also received CE Mark approval for commercialization in the European Union and the countries in Asia and Latin America that recognize the CE Mark. The company also provides the SEVEN PLUS, which incorporates additional user interface and algorithm enhancements that are intended to make its glucose monitoring function customizable. Its SEVEN PLUS has FDA and CE Mark approvals. DexCom has a collaboration agreement with Edwards Lifesciences LLC to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. It also has development agreement with Insulet Corporation to integrate its continuous glucose monitoring technology into Insuletís wireless, handheld OmniPod System Personal Diabetes Manager; and a joint development agreement with Animas Corporation to integrate its continuous glucose monitoring technology into Animas insulin pumps. The company was founded in 1999 and is headquartered in San Diego, California.

Recent News: "DexCom, Inc."